Innovative immunological and target therapies for NMIBC: Recent clinical trial data shaping the future : Episode 1
Opinion
Video
Unmet Needs & Standard of Care for Intermediate-High Risk NMIBC
Gary D. Steinberg, MD, discusses the unmet needs and current standard of care for patients with intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC).
Video Player is loading.
- What are some of the unmet needs in the treatment of non-muscle-invasive bladder cancer (NMIBC)?
- Patients with intermediate and high risk NMIBC
- Disease burden/effects on QoL
2. What is the current standard of care for patients with intermediate-risk or high risk NMIBC?
- Surgical resection
- Discuss shortage of BCG
Related Videos
Using Ultrasensitive PSA Assays in Routine Practice
Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point
Outcomes in Black patients receiving darolutamide plus ADT for mHSPC
Key Benefits of PET in ccRCC Risk Stratification
Case 2: A 68-Year-Old Woman With Non–Muscle-Invasive Bladder Cancer
Early Detection of ccRCC
Comparing the safety profile of darolutamide with other androgen receptor inhibitors in Black patients
Study findings highlight gender gaps in oncology authorship and citation
Targeted Therapy in mHSPC: Effects of Mutation Absence
Treatment Strategies for Symptomatic Bone Metastases in mHSPC
Related Content
